Press Releases & Event Reports

Microlife's upper arm monitors now have proven accuracy even in critical patients

EDTNA/ERCA Congress, Florence, September 15th 2007
Microlife's upper arm monitors are shown to accurately measure blood pressure even in patients with severe arterio-sclerosis in End Stage Renal Disease (ESRD), according to a paper published in the European Renal Disease magazine last month.⁽¹
The study shows Microlife's BP 3AC1-1PC monitor is the first oscillometric device to measure blood pressure accurately against a mercury sphygmomanometer (the gold standard) in a highly critical patient group.⁽²Leading the way in international validation protocol Microlife's upper arm monitors have received the highest possible grading (A/A) in an adult population according to the British Hypertension Society's (BSH) protocol.⁽³ In addition to this, the study now shows that Microlife's upper arm monitors are accurate even in very critical or risky patients where measurement is difficult such as in, ESRD, pregnancy and pre-eclampsia.⁽⁴
In his study, Professor Pickering and the team pointed out; "No study to date has validated an oscillometric home BP monitor against mercury sphygmomanometry in an ESRD population. The Microlife BP 3AC1-1PC was found to accurately measure BP in ESRD patients."
Bernd Jaenecke, Product Manager at Microlife said; "Microlife's blood pressure monitors contain unique patented technologies that allow for a more reliable reading. The technology allows a better characterization of blood pressure than conventional methods which is what makes them so reliable and accurate."
Microlife pride themselves in developing and introducing technologically advanced, pioneering products to the European market, President of Microlife, Ty-Minh Tan said; " Our devices are as accurate as clinic monitors which cost more than thousand US dollars, but ours are much more affordable. They not only have unique patented technology but are also being recommended by clinical leaders who are carrying out these important independent studies, which are helping us to lead the way in worldwide hypertension control."
Further information on the Microlife range of blood pressure monitors can be found at www.microlife.com.

Reference
⁽¹ European Renal Disease 2007, Issue 1, pp 38 - 40
⁽² Aliza M. Thompson, Kazuo Eguchi, Michael E. Reznik, Samir S. Shah and Thomas G. Pickering. Validation of an oscillometric home blood pressure monitor in an end-stage renal disease population and the effect of arterial stiffness on its accuracy. Department of Medicine, Behavioral Cardiovascular Health and Hypertension Program and Division of Nephrology, Columbia University, New York, New York, USA; Blood Pressure Monitoring 2007, 12:227'232.
⁽³ Alexandra C. Cuckson, Annemarie Reinders, Husain, Shabeeh and Andrew H. Shennan. Validation of the Microlife BP 3BTO-A oscillometric blood pressure monitoring device according to a modified British Hypertension Society protocol. Maternal and Fetal Research Unit, GKT School of Medicine, 10th floor North Wing, St Thomas' Hospital, Lambeth Palace Road, London, UK, Blood Pressure Monitoring 2002, 7:319-324.
⁽⁴ Reinders A, Cuckson AC, Lee J and Shennan AH. The Microlife 3BTO-A: An accurate automated device for use in adults and pregnancy. Maternal and Fetal Research Unit
GKT School of Medicine, St Thomas' Hospital, London, UK.

About Microlife
Microlife is one of the world leader's in the development and manufacturing of medical diagnostic equipment for home and medical use. Blood pressure monitors, digital thermometers and peak flow meters are Microlife's core business. A global company with offices in Taiwan, Switzerland and United States, Microlife is known for its high quality products and its worldwide distribution network. Microlife exports over 35 million units each year to all parts of the world. Each unit utilizes leading edge technology for monitoring key health indicators. The Microlife family consists of more than 2400 dedicated employees worldwide and is committed to continued research and development in medical devices that enable people to responsibly manage their own health.